EICHORCondition: Acute Tubulo-Interstitial Nephritis · Sponsor: Region MidtJylland Denmark
Interested? Contact the study team ↓
A Prospective randomized trial with a primary objective to investigate the effect ofprdenisolone treatment in acute interstitial nephritis
This description comes directly from the study's public registry record.
Frank Mose, MD · +4528531257 · frchri@rm.dk
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Biopsy verified AIN * Clinical suspicion of AIN * Age \> 18 years * One of following criteria: * Plasma creatinine \> 120 µmol/L or * Plasma creatinine increase \> 30 µmol/L or increase \> 50 % of baseline plasma creatinine * Fertile women are included Exclusion Criteria: * No ability to give informed consent * Immunosuppressive treatment (including prednisolone) within 3 months before biopsy * Autoimmune disease * Prednisolone intolerance * Pregnancy or lactation * Active cancer (except basal cell carcinoma) * Short life expectancy (\< 6 months) * CKD stage IV-V * AIN secondary to or accompanied by glomerulonephritis, sarcoidosis or inherited interstitial renal disease * Previous participation Withdrawal criteria * Development of exclusion criterion * Withdrawal of consent
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Godstrup Hospital | Herning, Denmark | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04376216